A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
Trial details
- Registry ID
- NCT05178862
- Phase
- Phase 3
The FDA approved Fluconazole (Diflucan) on 29 Jan 1990.
Drug identity checked against registry records
Also recorded as Diflucan
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral FluconazoleNCT05178862 | SCYX | Phase 3 | Terminated | 2025-11-07Actual |
| Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive CandidiasisNCT02244606 | SCYX | Phase 2 | Completed | 2016-06Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1990-01-29Day | Fluconazole | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA019949", "applicant_as_listed_by_fda": "PFIZER", "brand_names": ["DIFLUCAN"], "active_ingredients": ["FLUCONAZOLE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19900129", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |